These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23992249)

  • 1. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
    Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
    Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
    Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR; Abercrombie ED
    J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
    J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of L-DOPA pharmacological activity by MAO inhibitors.
    Finberg JP; Sader-Mazbar O
    J Neural Transm (Vienna); 2007; 114(6):801-5. PubMed ID: 17417741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.
    Miller DW; Abercrombie ED
    J Neurochem; 1999 Apr; 72(4):1516-22. PubMed ID: 10098856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
    Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
    Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T; Lamensdorf I; Finberg JP
    Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.
    Navailles S; Lagière M; Contini A; De Deurwaerdère P
    ACS Chem Neurosci; 2013 May; 4(5):680-92. PubMed ID: 23541043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
    Prat G; Pérez V; Rubi A; Casas M; Unzeta M
    J Neural Transm (Vienna); 2000; 107(4):409-17. PubMed ID: 11215752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Frouni I; Kwan C; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2139-2144. PubMed ID: 32601846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
    Finberg JP; Youdim MB
    Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
    Navailles S; Bioulac B; Gross C; De Deurwaerdère P
    Neurobiol Dis; 2010 Apr; 38(1):136-43. PubMed ID: 20096781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.